Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study in Participants With Rheumatoid Arthritis
NCT01202773 · Eli Lilly and Company · PHASE3 · terminated · last registry update 2018-05-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Terminated not based on safety concerns, but due to insufficient efficacy.” | – | Registry record, Eli Lilly and Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF13B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-04-08Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Rituximab + Cyclophosphamide (NCT02260934)
- 2019-03-21Results posted on the registry: EMD Serono, Atacicept 75 mg + Atacicept 150 mg (NCT02070978)
- 2019-03-21Also stopped (terminated): EMD Serono, Atacicept 75 mg + Atacicept 150 mg (NCT02070978)
- 2019-03-20Results posted on the registry: Eli Lilly and Company, Tabalumab + Bortezomib IV (NCT01556438)
- 2019-03-18Results posted on the registry: Eli Lilly and Company, LY2127399 + Placebo (NCT00308282)
- 2019-03-01Results posted on the registry: Eli Lilly and Company, LY2127399 (NCT01253291)
- 2018-12-06Results posted on the registry: Eli Lilly and Company, LY2127399 + Placebo (NCT00689728)
- 2018-11-20Phase 3 first posted: Leiden University Medical Center, Belimumab Injection (NCT03747159)
- 2018-11-15Results posted on the registry: Eli Lilly and Company, LY2127399 + Placebo (NCT00882999)
- 2018-11-09Results posted on the registry: GlaxoSmithKline, Belimumab (NCT02880852)
- 2018-10-23Results posted on the registry: Eli Lilly and Company, LY2127399 (Tabalumab) + Placebo (NCT01253226)
- 2018-08-15Results posted on the registry: GlaxoSmithKline, Belimumab 10 mg/kg (NCT01649765)
- 2018-08-15Results posted on the registry: Eli Lilly and Company, Placebo + Dexamethasone (NCT01602224)
- 2018-07-10Results posted on the registry: Eli Lilly and Company, LY2127399 + Placebo (NCT00785928)
- 2018-06-19Results posted on the registry: Eli Lilly and Company, LY2127399 + Placebo every 2 weeks (NCT01205438)
- 2018-06-15Results posted on the registry: Eli Lilly and Company, Tabalumab Auto-Injector + Tabalumab Prefilled Syringe (NCT02041091)
- 2018-06-15Also stopped (terminated): Eli Lilly and Company, Tabalumab Auto-Injector + Tabalumab Prefilled Syringe (NCT02041091)
- 2018-06-12Results posted on the registry: Eli Lilly and Company, LY2127399 + Placebo every 2 weeks (NCT01196091)
- 2018-06-11Results posted on the registry: Eli Lilly and Company, LY2127399 (NCT01215942)
- 2018-06-11Also stopped (terminated): Eli Lilly and Company, LY2127399 (NCT01215942)
- 2018-05-17Results posted on the registry: Eli Lilly and Company, LY2127399 + Placebo (NCT01488708)
- 2018-05-17Also stopped (terminated): Eli Lilly and Company, LY2127399 + Placebo (NCT01488708)
- 2018-05-14Results posted on the registry: Eli Lilly and Company, LY2127399 (NCT01200290)
- 2018-05-08Results posted on the registry: Eli Lilly and Company, LY2127399 + Placebo Q2W (NCT01198002)
- 2018-05-08Also stopped (terminated): Eli Lilly and Company, LY2127399 + Placebo Q2W (NCT01198002)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision